Literature DB >> 12374588

Systematic review of the effect of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome.

Michael Salman1.   

Abstract

The objective was to evaluate the effects of therapeutic dietary supplements and drugs on cognitive function in subjects with Down syndrome. The study design was a systematic review of randomized controlled trials of dietary supplements and/or drugs reporting any assessment of cognitive function in subjects with Down syndrome. Eleven trials were identified with 373 randomized participants. None of the trials reported cognitive enhancing effect in subjects with Down syndrome. Meta-analysis was not conducted due to the heterogeneous nature of the population, interventions and outcome measures used. Overall, the quality of the trials was poor with few subjects and generally inadequate allocation concealment of the treatments given. This comprehensive systematic review provides no positive evidence that any combination of drugs, vitamins and minerals enhance either cognitive function or psychomotor development in people with Down syndrome. However, because of the small number of subjects involved and the overall unsatisfactory quality of the trials, an effect cannot be excluded at this point. At present there is no justification for the use of such regimes outside the context of large well designed trials. Parents of children with Down syndrome should be actively discouraged from giving these 'miracle drugs' to their children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12374588     DOI: 10.1053/ejpn.2002.0596

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  9 in total

1.  Giving antioxidants to infants with Down's syndrome.

Authors:  Tim Reynolds
Journal:  BMJ       Date:  2008-02-21

2.  Diagnosis and management of Down syndrome.

Authors:  Neerja Agarwal Gupta; Madhulika Kabra
Journal:  Indian J Pediatr       Date:  2013-10-15       Impact factor: 1.967

Review 3.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

4.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

5.  Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial.

Authors:  Jill M Ellis; Hooi Kuan Tan; Ruth E Gilbert; David P R Muller; William Henley; Robert Moy; Rachel Pumphrey; Cornelius Ani; Sarah Davies; Vanessa Edwards; Heather Green; Alison Salt; Stuart Logan
Journal:  BMJ       Date:  2008-02-21

Review 6.  Molecular genetic analysis of Down syndrome.

Authors:  David Patterson
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

Review 7.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

8.  Prenatal Screening of Trisomy 21: Could Oxidative Stress Markers Play a Role?

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Sławomir Ławicki; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

Review 9.  Novel Approaches to an Integrated Route for Trisomy 21 Evaluation.

Authors:  Angelika Buczyńska; Iwona Sidorkiewicz; Anna Trochimiuk; Sławomir Ławicki; Adam Jacek Krętowski; Monika Zbucka-Krętowska
Journal:  Biomolecules       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.